About 10–15% of AMD patients develop neovascular (wet or exudative) AMD, which is characterised by choroidal neovascularisation (CNV) driven by vascular endothelial growth factor (VEGF) production, and leads to sequelae such as subretinal haemorrhage, exudation and fibrosis. The gene discussed is VEGFA; the disease is age-related macular degeneration.